▶ 調査レポート

黄斑変性症(AMD)及びその他の網膜疾患の世界市場 2020年

• 英文タイトル:Global Macular Degeneration (AMD) and Other Retinal Diseases Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。黄斑変性症(AMD)及びその他の網膜疾患の世界市場 2020年 / Global Macular Degeneration (AMD) and Other Retinal Diseases Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / GIR201115842資料のイメージです。• レポートコード:GIR201115842
• 出版社/出版日:GlobalInfoResearch / 2020年10月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本書では、黄斑変性症(AMD)及びその他の網膜疾患の世界市場を調査対象にし、黄斑変性症(AMD)及びその他の網膜疾患の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析(北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ)、種類別分析(黄斑変性症、糖尿病性黄斑変性症、糖尿病性網膜症(DR)、網膜静脈閉塞症、加齢性黄斑変性症(wAMD)、加齢性黄斑変性症(dAMD)、その他)、用途別分析(病院、クリニック、その他)、市場予測(2021年~2025年)情報などを整理しました。
・市場概要
・企業情報:Regeneron Pharmaceuticals、Santen Pharmaceutical、Roche、Bayer HealthCare、Allergan、Novartis、Pfizer、Merck、Kanghong Pharma、GlaxoSmithKline Pharmaceuticals、Acucela、Valent Pharmaceuticals、IVERIC
・企業別売上、市場シェア
・黄斑変性症(AMD)及びその他の網膜疾患の地域別市場分析
・黄斑変性症(AMD)及びその他の網膜疾患の北米市場規模2015-2020:アメリカ、カナダ、メキシコ
・黄斑変性症(AMD)及びその他の網膜疾患のヨーロッパ市場規模2015-2020:ドイツ、イギリス、フランス、ロシアなど
・黄斑変性症(AMD)及びその他の網膜疾患のアジア市場規模2015-2020:日本、中国、韓国、インド、東南アジアなど
・黄斑変性症(AMD)及びその他の網膜疾患の南米市場規模2015-2020:ブラジル、アルゼンチンなど
・黄斑変性症(AMD)及びその他の網膜疾患の中東・アフリカ市場規模2015-2020:サウジアラビア、トルコ、エジプト、南アフリカなど
・黄斑変性症(AMD)及びその他の網膜疾患の種類別市場規模2015-2020:黄斑変性症、糖尿病性黄斑変性症、糖尿病性網膜症(DR)、網膜静脈閉塞症、加齢性黄斑変性症(wAMD)、加齢性黄斑変性症(dAMD)、その他
・黄斑変性症(AMD)及びその他の網膜疾患の用途別市場規模2015-2020:病院、クリニック、その他
・黄斑変性症(AMD)及びその他の網膜疾患の世界市場予測2021-2025:地域別、種類別、用途別
・調査の結果・結論

Market Overview
The global Macular Degeneration (AMD) and Other Retinal Diseases market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Macular Degeneration (AMD) and Other Retinal Diseases market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Macular Degeneration (AMD) and Other Retinal Diseases market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Macular Degeneration (AMD) and Other Retinal Diseases market has been segmented into:
Macular Degeneration
Diabetic Macular Edema
Diabetic Retinopathy(DR)
Retinal Vein Occlusion
Wet Age-Related Macular Degeneration (wAMD)
Dry Age-Related Macular Degeneration (dAMD)
Other

By Application, Macular Degeneration (AMD) and Other Retinal Diseases has been segmented into:
Hospital
Clinic
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Macular Degeneration (AMD) and Other Retinal Diseases market presented in the report. This section sheds light on the sales growth of different regional and country-level Macular Degeneration (AMD) and Other Retinal Diseases markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Macular Degeneration (AMD) and Other Retinal Diseases market.

The report offers in-depth assessment of the growth and other aspects of the Macular Degeneration (AMD) and Other Retinal Diseases market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Macular Degeneration (AMD) and Other Retinal Diseases Market Share Analysis
Macular Degeneration (AMD) and Other Retinal Diseases competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Macular Degeneration (AMD) and Other Retinal Diseases sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Macular Degeneration (AMD) and Other Retinal Diseases sales, revenue and market share for each player covered in this report.

The major players covered in Macular Degeneration (AMD) and Other Retinal Diseases are:
Regeneron Pharmaceuticals
Santen Pharmaceutical
Roche
Bayer HealthCare
Allergan
Novartis
Pfizer
Merck
Kanghong Pharma
GlaxoSmithKline Pharmaceuticals
Acucela
Valent Pharmaceuticals
IVERIC

レポート目次

Table of Contents

1 Macular Degeneration (AMD) and Other Retinal Diseases Market Overview
1.1 Product Overview and Scope of Macular Degeneration (AMD) and Other Retinal Diseases
1.2 Classification of Macular Degeneration (AMD) and Other Retinal Diseases by Type
1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type in 2019
1.2.3 Macular Degeneration
1.2.4 Diabetic Macular Edema
1.2.5 Diabetic Retinopathy(DR)
1.2.6 Retinal Vein Occlusion
1.2.7 Wet Age-Related Macular Degeneration (wAMD)
1.2.8 Dry Age-Related Macular Degeneration (dAMD)
1.2.9 Other
1.3 Global Macular Degeneration (AMD) and Other Retinal Diseases Market by Application
1.3.1 Overview: Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market by Regions
1.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Macular Degeneration (AMD) and Other Retinal Diseases (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Macular Degeneration (AMD) and Other Retinal Diseases Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Macular Degeneration (AMD) and Other Retinal Diseases Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Macular Degeneration (AMD) and Other Retinal Diseases Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Macular Degeneration (AMD) and Other Retinal Diseases Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Macular Degeneration (AMD) and Other Retinal Diseases Status and Prospect (2015-2025)
2 Company Profiles
2.1 Regeneron Pharmaceuticals
2.1.1 Regeneron Pharmaceuticals Details
2.1.2 Regeneron Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Regeneron Pharmaceuticals SWOT Analysis
2.1.4 Regeneron Pharmaceuticals Product and Services
2.1.5 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.2 Santen Pharmaceutical
2.2.1 Santen Pharmaceutical Details
2.2.2 Santen Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Santen Pharmaceutical SWOT Analysis
2.2.4 Santen Pharmaceutical Product and Services
2.2.5 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bayer HealthCare
2.4.1 Bayer HealthCare Details
2.4.2 Bayer HealthCare Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bayer HealthCare SWOT Analysis
2.4.4 Bayer HealthCare Product and Services
2.4.5 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.5 Allergan
2.5.1 Allergan Details
2.5.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Allergan SWOT Analysis
2.5.4 Allergan Product and Services
2.5.5 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis SWOT Analysis
2.6.4 Novartis Product and Services
2.6.5 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pfizer SWOT Analysis
2.7.4 Pfizer Product and Services
2.7.5 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Merck SWOT Analysis
2.8.4 Merck Product and Services
2.8.5 Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.9 Kanghong Pharma
2.9.1 Kanghong Pharma Details
2.9.2 Kanghong Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Kanghong Pharma SWOT Analysis
2.9.4 Kanghong Pharma Product and Services
2.9.5 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.10 GlaxoSmithKline Pharmaceuticals
2.10.1 GlaxoSmithKline Pharmaceuticals Details
2.10.2 GlaxoSmithKline Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 GlaxoSmithKline Pharmaceuticals SWOT Analysis
2.10.4 GlaxoSmithKline Pharmaceuticals Product and Services
2.10.5 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.11 Acucela
2.11.1 Acucela Details
2.11.2 Acucela Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Acucela SWOT Analysis
2.11.4 Acucela Product and Services
2.11.5 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.12 Valent Pharmaceuticals
2.12.1 Valent Pharmaceuticals Details
2.12.2 Valent Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Valent Pharmaceuticals SWOT Analysis
2.12.4 Valent Pharmaceuticals Product and Services
2.12.5 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
2.13 IVERIC
2.13.1 IVERIC Details
2.13.2 IVERIC Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 IVERIC SWOT Analysis
2.13.4 IVERIC Product and Services
2.13.5 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Macular Degeneration (AMD) and Other Retinal Diseases Players Market Share
3.2.2 Top 10 Macular Degeneration (AMD) and Other Retinal Diseases Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Market Share by Regions
4.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
4.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
4.5 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
5 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries
5.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
5.2 USA Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
5.3 Canada Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
5.4 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries
6.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
6.2 Germany Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
6.3 UK Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
6.4 France Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
6.5 Russia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
6.6 Italy Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries
7.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
7.2 China Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
7.3 Japan Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
7.4 Korea Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
7.5 India Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
8 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries
8.1 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
8.2 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
8.3 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Macular Degeneration (AMD) and Other Retinal Diseases by Countries
9.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
9.2 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
9.3 UAE Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
9.4 Egypt Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
9.5 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Market Share by Type (2015-2020)
10.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type (2019-2024)
10.3 Macular Degeneration Revenue Growth Rate (2015-2025)
10.4 Diabetic Macular Edema Revenue Growth Rate (2015-2025)
10.5 Diabetic Retinopathy(DR) Revenue Growth Rate (2015-2025)
10.6 Retinal Vein Occlusion Revenue Growth Rate (2015-2025)
10.7 Wet Age-Related Macular Degeneration (wAMD) Revenue Growth Rate (2015-2025)
10.8 Dry Age-Related Macular Degeneration (dAMD) Revenue Growth Rate (2015-2025)
10.9 Other Revenue Growth Rate (2015-2025)
11 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Segment by Application
11.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2015-2020)
11.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast (2021-2025)
12.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast (2021-2025)
12.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Regions (2021-2025)
12.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
12.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
12.6 South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Macular Degeneration (AMD) and Other Retinal Diseases by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Regeneron Pharmaceuticals Corporate Information, Location and Competitors
Table 6. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 7. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 8. Regeneron Pharmaceuticals SWOT Analysis
Table 9. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 10. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Santen Pharmaceutical Corporate Information, Location and Competitors
Table 12. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 13. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2018-2019)
Table 14. Santen Pharmaceutical SWOT Analysis
Table 15. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 16. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Roche Corporate Information, Location and Competitors
Table 18. Roche Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 19. Roche Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 20. Roche SWOT Analysis
Table 21. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 22. Roche Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Bayer HealthCare Corporate Information, Location and Competitors
Table 24. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 25. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 26. Bayer HealthCare SWOT Analysis
Table 27. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 28. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Allergan Corporate Information, Location and Competitors
Table 30. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 31. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 32. Allergan SWOT Analysis
Table 33. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 34. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Novartis Corporate Information, Location and Competitors
Table 36. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 37. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 38. Novartis SWOT Analysis
Table 39. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 40. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Pfizer Corporate Information, Location and Competitors
Table 42. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 43. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 44. Pfizer SWOT Analysis
Table 45. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 46. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Merck Corporate Information, Location and Competitors
Table 48. Merck Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 49. Merck Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 50. Merck SWOT Analysis
Table 51. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 52. Merck Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Kanghong Pharma Corporate Information, Location and Competitors
Table 54. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 55. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 56. Kanghong Pharma SWOT Analysis
Table 57. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 58. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. GlaxoSmithKline Pharmaceuticals Corporate Information, Location and Competitors
Table 60. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 61. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 62. GlaxoSmithKline Pharmaceuticals SWOT Analysis
Table 63. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 64. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Acucela Corporate Information, Location and Competitors
Table 66. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 67. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 68. Acucela SWOT Analysis
Table 69. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 70. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Valent Pharmaceuticals Corporate Information, Location and Competitors
Table 72. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 73. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 74. Valent Pharmaceuticals SWOT Analysis
Table 75. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 76. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. IVERIC Corporate Information, Location and Competitors
Table 78. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Major Business
Table 79. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Total Revenue (USD Million) (2017-2018)
Table 80. IVERIC SWOT Analysis
Table 81. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product and Solutions
Table 82. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Players (2015-2020)
Table 84. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Players (2015-2020)
Table 85. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Regions (2015-2020)
Table 86. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Regions (2015-2020)
Table 87. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
Table 88. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Table 89. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Countries (2015-2020)
Table 90. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Countries (2015-2020)
Table 91. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Countries (2015-2020)
Table 92. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Table 93. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Countries (2015-2020)
Table 94. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Table 95. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) by Type (2015-2020)
Table 96. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Type (2015-2020)
Table 97. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Forecast by Type (2021-2025)
Table 98. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Application (2015-2020)
Table 99. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Application (2015-2020)
Table 100. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Forecast by Application (2021-2025)
Table 101. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Macular Degeneration (AMD) and Other Retinal Diseases Picture
Figure 2. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type in 2019
Figure 3. Macular Degeneration Picture
Figure 4. Diabetic Macular Edema Picture
Figure 5. Diabetic Retinopathy(DR) Picture
Figure 6. Retinal Vein Occlusion Picture
Figure 7. Wet Age-Related Macular Degeneration (wAMD) Picture
Figure 8. Dry Age-Related Macular Degeneration (dAMD) Picture
Figure 9. Other Picture
Figure 10. Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application in 2019
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Other Picture
Figure 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share in 2019
Figure 23. Global Top 10 Players Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Regions (2015-2020)
Figure 27. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Regions in 2018
Figure 28. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 29. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 31. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 33. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Figure 34. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries in 2019
Figure 35. USA Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 36. Canada Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 38. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries in 2019
Figure 40. Germany Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 41. UK Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 42. France Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 43. Russia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 44. Italy Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries in 2019
Figure 47. China Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 48. Japan Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 49. Korea Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 50. India Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 52. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Figure 53. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries in 2019
Figure 54. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 59. UAE Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue and Growth Rate (2015-2020)
Figure 62. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Type (2015-2020)
Figure 63. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Type in 2019
Figure 64. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Type (2021-2025)
Figure 65. Global Macular Degeneration Revenue Growth Rate (2015-2020)
Figure 66. Global Diabetic Macular Edema Revenue Growth Rate (2015-2020)
Figure 67. Global Diabetic Retinopathy(DR) Revenue Growth Rate (2015-2020)
Figure 68. Global Retinal Vein Occlusion Revenue Growth Rate (2015-2020)
Figure 69. Global Wet Age-Related Macular Degeneration (wAMD) Revenue Growth Rate (2015-2020)
Figure 70. Global Dry Age-Related Macular Degeneration (dAMD) Revenue Growth Rate (2015-2020)
Figure 71. Global Other Revenue Growth Rate (2015-2020)
Figure 72. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Application (2015-2020)
Figure 73. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Share by Application in 2019
Figure 74. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Application (2021-2025)
Figure 75. Global Hospital Revenue Growth Rate (2015-2020)
Figure 76. Global Clinic Revenue Growth Rate (2015-2020)
Figure 77. Global Other Revenue Growth Rate (2015-2020)
Figure 78. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
Figure 82. Europe Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
Figure 84. South America Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel